Creative BioMolecules, Genetics Institute, Stryker Corp. deal

The companies cross-licensed their worldwide patent rights in the bone morphogenic/osteogenic (BMP/OP) protein family on a royalty-free basis. The agreeement, which covers both issued patents and pending patent applications, will allow the companies to commercialize their lead compounds, which are in clinical trials for bone repair and regeneration, without risk of patent litigation. ...